Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is a member of the large ErbB family and an important oncogene in many solid tumors. Pyrotinib has been approved for the treatment of HER2-positive, recurrent, or metastatic breast cancer. However, there are very few clinical studies on pyr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jianzheng, Zhang, Baiwen, Cheng, Xiaojiao, Li, Qingli, Lv, Huifang, Nie, Caiyun, Chen, Beibei, Xu, Weifeng, Zhao, Jing, He, Yunduan, Tu, Shuiping, Chen, Xiaobing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975634/
https://www.ncbi.nlm.nih.gov/pubmed/35368895
http://dx.doi.org/10.1155/2022/4233782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975634/
https://www.ncbi.nlm.nih.gov/pubmed/35368895
http://dx.doi.org/10.1155/2022/4233782

Ejemplares similares